

IN THE SPECIFICATION

Page 1, between lines 4 and 5, insert --This invention was made in part with government support under Grant Numbers CA59327, HL43757 and DK42760, awarded by the National Institutes of Health. The U.S. Government has certain rights in this invention.--

IN THE CLAIMS

Please add the following new claims:

17. (New) A kit for site-specifically transforming cells *in vivo* comprising a catheter and a nucleic acid comprising a gene encoding p21.
18. (New) The kit of claim 17, wherein the catheter is a single balloon catheter.
19. (New) The kit of claim 17, wherein the catheter is a double balloon catheter.
20. (New) The kit of claim 17, further comprising a pharmaceutical carrier.
21. (New) The kit of claim 17, wherein the pharmaceutical carrier comprises the nucleic acid.
22. (New) The kit of claim 17, wherein the nucleic acid is an expression vector.
23. (New) The kit of claim 22, wherein the expression vector comprises a viral promoter.
24. (New) The kit of claim 23, wherein the viral promoter is a CMV promoter.
25. (New) The kit of claim 23, wherein the viral promoter is an RSV promoter.
26. (New) The kit of claim 17, wherein a viral particle comprises the nucleic acid.
27. (New) The kit of claim 26, wherein the viral particle is an adenovirus particle.
28. (New) The kit of claim 26, wherein the viral particle is a retrovirus particle.
29. (New) The kit of claim 17, further comprising a liposome.
30. (New) The kit of claim 29, wherein the liposome comprises the nucleic acid.
31. (New) The kit of claim 17, wherein the nucleic acid further comprises a second gene.


32. (New) The kit of claim 31, wherein the second gene encodes an immunotherapeutic agent, genetic therapeutic, cytokine, or prodrug converting enzyme.
33. (New) The kit of claim 32, wherein the prodrug converting enzyme is thymidine kinase.
34. (New) The kit of claim 31, wherein the gene encoding p21 and the second gene are operatively linked.
35. (New) The kit of claim 34, wherein the gene encoding p21 and the second gene are operatively linked such that they form a fusion protein.
36. (New) The kit of claim 35, wherein the fusion protein is a p21-thymidine kinase fusion protein.
37. (New) A kit for treating a disease in a patient comprising a syringe and a nucleic acid comprising a gene encoding p21.
38. (New) The kit of claim 37, further comprising a pharmaceutical carrier.
39. (New) The kit of claim 38, wherein the pharmaceutical carrier comprises the nucleic acid.
40. (New) The kit of claim 37, wherein the nucleic acid is an expression vector.
41. (New) The kit of claim 40, wherein the expression vector comprises a viral promoter.
42. (New) The kit of claim 41, wherein the viral promoter is a CMV promoter.
43. (New) The kit of claim 41, wherein the viral promoter is an RSV promoter.
44. (New) The kit of claim 37, wherein a viral particle comprises the nucleic acid.
45. (New) The kit of claim 44, wherein the viral particle is an adenovirus particle.
46. (New) The kit of claim 44, wherein the viral particle is a retrovirus particle.
47. (New) The kit of claim 37, further comprising a liposome.
48. (New) The kit of claim 47, wherein the liposome comprises the nucleic acid.

49. (New) The kit of claim 37, wherein the nucleic acid further comprises a second gene.
50. (New) The kit of claim 49, wherein the second gene encodes an immunotherapeutic agent, genetic therapeutic, cytokine, or prodrug converting enzyme.
51. (New) The kit of claim 50, wherein the prodrug converting enzyme is thymidine kinase.
52. (New) The kit of claim 49, wherein the gene encoding p21 and the second gene are operatively linked.
53. (New) The kit of claim 52, wherein the gene encoding p21 and the second gene are operatively linked such that they form a fusion protein.
54. (New) The kit of claim 53, wherein the fusion protein is a p21-thymidine kinase fusion protein.

REMARKS

Support for the newly added claims can be found throughout the specification. In particular, support for the claims can be found at least at pages 5-12; Example 1, pages 14-15; Example 2, pages 24-25; and within U.S. Patent No. 5,328,470, which is incorporated by reference at page 10, line 24.

Respectfully submitted,



Thomas J. Wrona
Registration No. 44,410

BRINKS HOFER GILSON & LIONE
P.O. BOX 10395
CHICAGO, ILLINOIS 60610
(312) 321-4200